Oxxon Therapeutics
Oxford
About Oxxon Therapeutics
Oxxon Therapeutics™ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the company has built an initial pipeline through its patented Hi-8™ PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease. The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV. In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $23.6M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2003)
- Website: oxti.com
- Phone: +4401865398100
Industries & Categories
Alternative Medicine, Biotechnology, Health Care, Hospitality, Medical
Canonical: https://fsome.com/organization/oxxon-therapeutics-2762697 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.